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Executive Summary 
 
 
Substance identification 
p-Fluoro-butyrylfentanyl (IUPAC name: N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-
yl]butanamide) is a synthetic analog of the opioid analgesic fentanyl. In Europe, it was first 
reported in 2014 followed by the Untied States of America in 2015. Samples obtained from 
seizures and collections suggest that p-fluoro-butyrylfentanyl appears in powder, tablet, nasal 
spray and e-liquid form. Examples exist where it might be found in samples mixed with heroin. 
 
WHO Review History 
p-Fluoro-butyrylfentanyl has not been previously pre-reviewed or critically reviewed. 
 
Chemistry 
There is no specific information available about the routes of synthesis employed for the p-fluoro-
butyrylfentanyl products circulating on the drug market but straightforward methods for its 
preparation exist without requiring access to precursors that are controlled internationally. Routes 
of synthesis also exist that might require the use of a controlled precursor. 
 
Ease of convertibility into controlled substances 
p-Fluoro-butyrylfentanyl could be converted to its isomer p-fluoro-isobutyrylfentanyl (IUPAC 
name: N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide), which is 
listed in Schedule I of the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 
Protocol. 
 
Similarity to known substances / Effects on the central nervous system 
Data from human studies are not available but the information available so far suggests that the 
effects induced by p-fluoro-butyrylfentanyl are also shared by other synthetic opioids such as 
fentanyl and heroin.  
 
General pharmacology 
Pharmacological studies have shown that p-fluoro-butyrylfentanyl is qualitatively similar to 
fentanyl and heroin. p-Fluoro-butyrylfentanyl binds to μ-opioid receptors (MOR) with high 
selectivity over the κ- and δ-opioid receptors and has been shown to act as a partial agonist at 
MOR in a [35S]GTPγS binding assay. Similar to both fentanyl and morphine, p-fluoro-
butyrylfentanyl was also shown to induce locomotor activity and antinociceptive effects in mice. 
Antinociceptive effects were attenuated by pre-treatment with naltrexone. 
 
Toxicology 
Data on the toxicology of p-fluoro-butyrylfentanyl could not be identified.  
 
Adverse reactions in humans 
p-Fluoro-butyrylfentanyl has been detected in biological samples obtained from fatal intoxication 
cases although unambiguous differentiation from  the p-fluoro-isobutyrylfentanyl isomer was not 
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always possible. A report detailing an acute intoxication revealed that clinical features included 
disorientation, slurred speech and hypotension.  
 
Dependence potential 
No studies available. Experience with fentanyl and other synthetic opioids suggest that the 
dependence potential might extend to p-fluoro-butyrylfentanyl but further studies are warranted 
to explore this. 
 
Abuse potential 
Whilst no formal studies exist, the limited available information indicates that p-fluoro-
butyrylfentanyl is used by experimental users (psychonauts) and people who also use synthetic 
opioids and opiates. It is likely that p-fluoro-butyrylfentanyl will be associated with abuse liability.  
 
Therapeutic applications / usefulness 
p-Fluoro-butyrylfentanyl is not known to have any therapeutic uses.  
 
Listing on WHO Model List of Essential Medicines 
p-Fluoro-butyrylfentanyl is not listed. 
 
Marketing authorizations 
p-Fluoro-butyrylfentanyl is not known to have any marketing authorizations. 
 
Industrial use 
p-Fluoro-butyrylfentanyl is not known to have any agricultural, industrial or cosmetic uses even 
though it is available for purchase as a ‘research chemical’. 
 
Non-medical use 
The mode of use may involve the combinational use (intentionally or unintentionally) of other 
drugs and users may be unaware of the exact dose or compound being ingested (by whatever 
route). Similar to other fentanils, p-fluoro-butyrylfentanyl may be administered as a solution (e.g. 
using nasal sprays), orally as a powder (including in capsules or tablets), or by insufflation of a 
powder; it can also be administered sublingually or intranasally via a spray; administered by 
injection (intramuscular or intravenous) or inhaled by vaporizing.  
 
Nature and magnitude of public health problems 
Use of p-fluoro-butyrylfentanyl appears to be limited to recreational substance users rather than 
the general population. Marginalized and vulnerable opioid users including those who inject such 
substances also use fentanyl analogs. However, users may not be aware of using them and the 
high potency associated with fentanyl analogs might result in increased risks of life-threatening 
overdoses. At the same time, fentanyl and its analogs pose a serious risk of accidental exposure to 
such products with the potential for subsequent poisoning of the public, law enforcement and 
emergency personnel, as well as medical/laboratory personnel. 
 
Licit production, consumption, and international trade 
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p-Fluoro-butyrylfentanyl is not known to have any agricultural, industrial or cosmetic uses even 
though it is available for purchase as a ‘research chemical’. 
 
Illicit manufacture and traffic 
So far the total number of reports describing the identification of p-fluoro-butyrylfentanyl seems 
comparatively low but it an increase in detections has been reported in the US. p-Fluoro-
butyrylfentanyl can be purchased from Internet retailers. 
 
Current international controls and their impact 
p-Fluoro-butyrylfentanyl is not controlled under the 1961, 1971 or 1988 United Nations 
Conventions. 
 
Current and past national controls 
p-Fluoro-butyrylfentanyl is controlled in some UN Member States.  
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1.  Substance identification  
A. International Nonproprietary Name (INN) 
Not applicable. 
B. Chemical Abstract Service (CAS) Registry Number 
244195-31-1 (free base) 
C. Other Chemical Names 
N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide 
N-(4-Fluorophenyl)-N-(1-phenethyl-4-piperidinyl)butanamide 
 p-Fluoro-butyrylfentanyl 
para-Fluoro-butyrylfentanyl 
4-Fluoro-butyrylfentanyl 
4′-Fluoro-butyryfentanyl 
p-Fluoro-butanoylfentanyl 
para-Fluoro-butanoylfentanyl 
4-Fluoro-butanoylfentanyl 
4′-Fluoro-butanoylfentanyl 
p-Fluoro-butyrfentanyl 
para-Fluoro-butyrfentanyl 
4-Fluoro-butyrfentanyl 
4′-Fluoro-butyrfentanyl 
D. Trade Names 
Not applicable. 
E. Street Names 
4-FBF; 4PBF; PFBF; p-FBF; street names also include chemical names. 
F. Physical Appearance 
The hydrochloride salt of p-fluoro-butyrylfentanyl has been described as an off-
white powder1 1 and a neat2 and crystalline solid.3 In its pure form, p-fluoro-
butyrylfentanyl hydrochloride is expected to be odorless. 
G. WHO Review History 
p-Fluoro-butyrylfentanyl has not been previously pre-reviewed or critically 
reviewed. A direct critical review is proposed based on information brought to 
WHO’s attention that p-fluoro-butyrylfentanyl is clandestinely manufactured, of 
especially serious risk to public health and society, and of no recognized therapeutic 
use by any party. Preliminary data collected from literature and different countries 
indicated that this substance may cause substantial harm and that it has no medical 
use. 
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2. Chemistry 
A. Chemical Name 
IUPAC Name:  
   N-(4-Fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide 
CA Index Name:  
N-(4-Fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]butanamide 
B. Chemical Structure 
Free base: 
 
 
Molecular Formula: C23H29FN2O 
Molecular Weight: 368.50 g/mol 
  
C. Stereoisomers 
Not applicable. 
D. Methods and Ease of Illicit Manufacturing 
Information on the synthesis of p-fluoro-butyrylfentanyl products encountered on 
the market could not be identified. It is expected that the methods used for the 
synthesis of fentanyle.g.4-8 are equally applicable to p-fluoro-butyrylfentanyl by 
changing the widely available reagents accordingly. One procedure describing the 
preparation of fentanyl has also been published on the Internet.9 The methods used 
for the synthesis of such fentanyl analogs are straightforward. In the analytical 
characterization study published by Ohta and Suzuki,10 p-fluoro-butyrylfentanyl and 
other analogs have been prepared. The methodology was not included in the 
investigation but the authors commented on the adaptation of a procedure 
published by Van Bever and co-workers from Janssen Pharmaceutica in 1974.5 The 
reaction scheme arising from this (assuming that the procedure was followed 
verbatim) is summarized in Figure 1A. The carbamate starting material (a) 
undergoes reductive amination with 4-fluoroaniline via the imine intermediate (b) 
to form methyl 4-[(4-fluorophenyl)amino]piperidine-1-carboxylate (c). Acylation 
with butanoic anhydride (or butanoyl chloride) yields (d), which converts under 
reflux with acid to N-(4-fluorophenyl)piperidin-4-amine (e). Substitution with (2-
chloroethyl)benzene (or (2-bromoethyl)benzene) gives N-(4-fluorophenyl)-1-(2-
phenylethyl)piperidin-4-amine (f) with the final product (g) being formed by 
O
NN
F
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acylation with butanoic anhydride (or butanoyl chloride). Intermediate (f) 
represents the fluorinated analog of N-phenyl-1-(2-phenylethyl)piperidin-4-amine 
(4-ANPP), which is a controlled precursor11 used for the preparation of fentanyl9 
and other analogs. The fluorinated 4-F-ANPP (f) could also be prepared from 1-(2-
phenylethyl)piperidin-4-one (also known as N-phenethyl-4-piperidone, NPP) and 4-
fluoroaniline. However, NPP is also listed in Table 1 of the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 
1988.11  
 
 
 
Figure 1. Examples of potential procedures. A. Synthesis of p-fluoro-butyrylfentanyl (g) according to Ohta and Suzuki
10
 
adapting the procedure published by Van Bever et al.
5
 i) 4-F(C6H4)NH2; ii) NaBH4; iii) (CH3CH2CH2CO)2O; iv) 48% HBr; v) 
PhCH2CH2X (X = Cl or Br); vi) (CH3CH2CH2CO)2O. B: Potential synthesis of p-fluoro-butyrylfentanyl (f) following one of 
the earliest procedures employed by Janssen.
4
 i) 4-F(C6H4)NH2; ii) acid catalyst (e.g. pTsOH); ii: LiAlH4; iii) 
(CH3CH2CH2CO)2O; iv) H2, Pd-C; v) PhCH2CH2Cl, KI, Na2CO3. 
 
 
Figure 1B outlines another potential approach based on one of the earliest 
procedures used for the preparation of fentanyl4 The starting material 1-
benzylpiperidin-4-one (a) undergoes reductive amination with 4-fluoroaniline (via 
imine (b)) to form 1-benzyl-N-(4-fluorophenyl)piperidin-4-amine (c), which 
undergoes acylation with either butanoic anhydride or butanoyl chloride to afford 
N-(1-benzylpiperidin-4-yl)-N-(4-fluorophenyl)butanamide (d). Debenzylation by 
O
NN
F
N O
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hydrogenation provides access to N-(4-fluorophenyl)-N-(piperidin-4-yl)butanamide 
(e). Alkylation of the piperidine nitrogen with either (2-chloroethyl)benzene or (2-
bromoethyl)benzene yields p-fluoro-butyrylfentanyl (f). 
 
E. Chemical Properties 
Melting point 
114–115 °C12 
Boiling point 
Information could not be identified. 
Solubility 
Hydrochloride salt: ~0.25 mg/mL in a 1:3 solution of dimethyl sulfoxide:phosphate 
buffered saline  (pH 7.2); ~5 mg/mL in ethanol; ~10 mg/mL in dimethyl sulfoxide 
and dimethylformamide.3 The free base is expected to be only sparingly soluble in 
water. A collected hydrochloride salt sample identified as p-fluoro-butyrylfentanyl 
was noted as being “soluble” in dichloromethane, methanol and water.13  
F. Identification and Analysis  
 
Identification, especially when available in larger quantities than normally 
encountered in forensic toxicological work, is straightforward. Presumptive color 
test results performed on submitted samples determined to contain p-fluoro-
butyrylfentanyl have been published in the public domain.14 Results from analytical 
studies have been published and include data on thin layer chromatography,10 gas 
chromatography electron ionization mass spectrometry (MS),1, 10, 12, 13, 15 
electrospray ionization tandem MS,12, 16-20 nuclear magnetic resonance 
spectroscopy,12 1, 13, immunoassays,21 ultraviolet–visible spectrophotometry,12 and 
Fourier transform infrared spectroscopy.13  
 
Analytical challenges may arise, for example when dealing with closely related 
isomers such as N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-
yl]propanamide (p-fluoro-isobutyrylfentanyl)22 that underwent critical review by the 
World Health Organization in 2017.23 In addition, both of these fentanils can also 
exist in the ortho- (2-fluorophenyl) or meta-fluoro (3-fluorophenyl) forms, which 
adds to the complexity. The implementation of adequate separation techniques 
might be needed to reduce the potential for misidentification, especially when 
dealing with samples (e.g. biological) that may only contain trace quantities. A case 
of mislabeling has been reported to the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) where a seized, powdered sample labeled as “4-F-BF” 
was determined to contain an N-benzyl analog instead.24 In this case, the 
unambiguous identity could not be established as the possibility existed that the 
seized compound might have represented up to six different isomers, that is, N-(1-
benzylpiperidin-4-yl)-N-(4-fluorophenyl)butanamide (three different fluorophenyl 
isomers) and N-(1-benzylpiperidin-4-yl)-N-(4-fluorophenyl)-2-methylpropanamide 
(three different fluorophenyl isomers). It is noteworthy that the N-benzyl analog 
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could be considered an intermediate formed during the synthesis of the 
corresponding fentanyl analog (Figure 1B, structure (d)). 
3. Ease of Convertibility Into Controlled Substances 
No information available. However, since p-fluoro-isobutyrylfentanyl is a controlled 
substance (Schedule I of the Single Convention on Narcotic Drugs of 1961, as 
amended by the 1972 Protocol), it appears conceivable that p-fluoro-
butyrylfentanyl could be converted by hydrolysis of the 4-N-butanoyl group with an 
acid (e.g. HCl) to N-(4-fluorophenyl)-1-(2-phenylethyl)piperidin-4-amine (4-F-ANPP), 
which in turn could be acylated again with 2-methylpropanoyl chloride or 2-
methylpropanoic anhydride. Examples for acid-induced hydrolysis exist, for 
example, for fentanyl25 and ohmefentanyl (N-[1-(2-hydroxy-2-phenylethyl)-3-
methylpiperidin-4-yl]-N-phenylpropanamide).26   
 
4. General Pharmacology 
A. Routes of administration and dosage 
Similar to other fentanils,27, 28 p-fluoro-butyrylfentanyl may be administered as a 
solution (e.g. using nasal sprays), orally as a powder (including in capsules or 
tablets), or by insufflation of a powder; it can also be administered sublingually or 
intranasally via a spray; administered by injection (intramuscular or intravenous) or 
inhaled by vaporizing. Information received by the EMCDDA based on analyses of 
seized and collected material and published literature involving adverse events 
suggests the existence of p-fluoro-butyrylfentanyl-containing powders, tablets, 
electronic cigarette liquid,12 and nasal spray formulations.16, 29, 30 User reports 
suggesting intravenous, sublingual (spray) and intranasal (spray) routes of 
administration of p-fluoro-butyrylfentanyl have been published on the 
Internet.e.g.31-33 Case report literature suggests that p-fluoro-butyrylfentanyl was 
orally administered in pill form.16 It has been estimated that oral doses may range 
from 300 μg (“low”) and “common” doses of 600–900 μg to “strong” doses of 900–
1200 μg.34 However, estimating the doses administered by users may not be 
possible as this appears to depend on factors such as the tolerance of the users, the 
use of other drugs, desired effects, and the route of administration.e.g.31-33, 35, 36 
B. Pharmacokinetics 
Detailed information specifically on p-fluoro-butyrylfentanyl could not be identified 
but it appears likely that the formation metabolic transformation products (e.g. N-
(4-fluorophenyl)-N-(piperidin-4-yl)butanamide, “nor-p-fluoro-butyrylfentanyl”16) 
follows similar mechanisms that were seen with the isomeric p-fluoro-
isobutyrylfentanyl23, 37 and other fentanils.27 “Insufflated” routes of administration 
have been suggested to induce effects in the 30–60 min range,34 which suggests 
that the desired effects may be short-lasting. For the reasons mentioned above 
however, such estimations should be viewed with caution. 
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C. Pharmacodynamics 
In vitro data: 
 
Current available data suggest that p-fluoro-butyrylfentanyl, similar to morphine 
and fentanyl, binds to μ-opioid receptors (MOR) with high selectivity over the κ- 
and δ-opioid receptors (KOR and DOR) (Table 1).38 Functional studies using the 
[35S]GTPγS binding assay also demonstrated that p-fluoro-butyrylfentanyl acted as a 
partial agonist at MOR and KOR, which meant that the test drug showed a reduced 
efficacy for receptor activation compared with morphine and fentanyl (Table 1). 
Compared to the recently controlled isomer p-fluoro-isobutyrylfentanyl (Ki = 0.451 
nM), determined under identical conditions, p-fluoro-butyrylfentanyl was found to 
show a comparable binding affinity at MOR. At the same time, p-fluoro-
isobutyrylfentanyl was ~6-times less potent (EC50 = 115 nM) than p-fluoro-
butyrylfentanyl although it acted as a full agonist with a maximum efficacy of 
91.6%23, 37 compared to 49.4% observed with p-fluoro-butyrylfentanyl.  
 
Table 1. Receptor binding and functional activity data for p-fluoro-butyrylfentanyl (modified from
38
).
a
 
MOR pFBF b Morphine Fentanyl DAMGO Naltrexone 
[3H]DAMGO binding Ki (nM) 
IC50 (nM) 
Hill coefficient 
0.516 ± 0.073 
3.58 ± 0.53 
-0.73 ± 0.07 
0.213 ± 0.019 
1.432 
-0.95 ± 0.02 
0.150 ± 0.030 
1.00 
-0.72 ± 0.07 
0.1313 ± 0.0050 
0.883 
-0.89 ± 0.06 
0.0793 ± 0.0042 
0.532 
-0.81 ± 0.36 
[35S]GTPγS binding 
Stimulation EC50 (nM) 
Maximal stimulation (%) c 
pFBF b 
17.9 ± 1.8 
49.4 ± 4.3 
Morphine 
31.0 ± 8.2 
83.3 ± 5.5 
Fentanyl 
17.9 ± 4.3 
81.2 ± 7.4 
DAMGO 
21.4 ± 4.2 
96.8 ± 1.9 
– 
– 
– 
DOR pFBF b Morphine Fentanyl DPDPE-OH Naltrexone 
[3H]DPDPE binding Ki (nM) 
IC50 (nM) 
Hill coefficient 
351 ± 63   
566 ± 92 
-0.74 ± 0.10 
111 ± 14 
182 
-0.96 ± 0.02 
242 ± 20 
391 
-0.93 ± 0.09 
2.96 ± 0.57 
5.0 
-0.94 ± 0.10 
14.2 ± 3.1 
23.8 
-1.03 ± 0.12 
[35S]GTPγS binding 
Stimulation EC50 (nM) 
Maximal stimulation (%) c 
pFBF b 
>10 μM 
6.7 ± 2.2 
Morphine 
870 ± 140 
77.3 ± 2.3 
Fentanyl 
1,190 ± 140 
58.0 ± 4.2 
DPDPE-OH 
7.22 ± 0.38 
100.97 ± 0.97 
– 
– 
– 
KOR pFBF b Morphine Fentanyl U-50,488H Nor-BNI 
[3H]U-69,593 binding Ki (nM) 
IC50 (nM) 
Hill coefficient 
501 ± 81 
1,130 ± 190 
-1.06 ± 0.08 
27.9 ± 2.7  
63.4 
-0.98 ± 0.06 
194 ± 20  
436 
-1.19 ± 0.17 
0.155 ± 0.048  
0.35 
-0.70 ± 0.03 
0.42 ± 0.16  
0.86 
-1.11 ± 0.23 
[35S]GTPγS binding pFBF b Morphine Fentanyl U-50,488H – 
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In vivo data: 
 
Locomotor activity studies (adult male CFW mice; subcutaneous administration; 
distances traveled during 120 min test sessions recorded in 10 min intervals) have 
been carried out comparing p-fluoro-butyrylfentanyl (tested 0.1, 1, 10, and 100 
mg/kg with fentanyl (0.1, 1 and 10 mg/kg) and morphine (1, 10, 100 and 180 
mg/kg).39 
 
p-Fluoro-butyrylfentanyl significantly increased distance traveled during several 
time intervals including at 10 mg/kg (10–80 min) and 100 mg/kg (10, 30–120 min). 
Fentanyl increased locomotion at 1 mg/kg (10–120 min), and 10 mg/kg (30–120 
min), and morphine increased distances traveled at 10 mg/kg (40–90 min), 100 
mg/kg (20–120 min), and 180 mg/kg (20–120 min). The dose-dependent activation 
of locomotor activity was confirmed to be qualitatively similar to fentanyl and 
morphine. As far as the total distances traveled were concerned, fentanyl induced 
the largest increase at 1 mg/kg followed by morphine at 180 mg/kg and 100 mg/kg, 
fentanyl at 10 mg/kg and p-fluoro-butyrylfentanyl at 10 mg/kg and 100 mg/kg. 39  
 
Antinociceptive effects (warm water tail-withdrawal test, 50°C, adult male CFW 
mice; subcutaneous administration) have been investigated and it was confirmed 
that p-fluoro-butyrylfentanyl increased the withdrawal latency consistent with 
delayed withdrawal times also observed with fentanyl and morphine used for 
comparison. Significant dose-dependent increases in tail withdrawal latencies were 
observed for all test drugs, which were attenuated by pre-treatment with 
naltrexone (Table 2). In this assay, p-fluoro-butyrylfentanyl showed 8.8% of the 
potency of fentanyl although it was 8.6-times more potent than morphine (Table 2). 
Stimulation EC50 (nM) 
Maximal stimulation (%) c 
370 ± 120 
51.3 ± 2.3 
83 ± 23 
86.8 ± 6.0 
362 ± 47 
72.9 ± 3.2 
1.15 ± 0.22 
93.6 ± 2.2 
– 
– 
a
 In receptor binding experiments, transfected Chinese hamster ovary (CHO) cells expressing human δ- and κ-opioid receptors and rat μ-
opioid receptors were used. DOR: delta opioid receptor; KOR: kappa opioid receptor; MOR: mu opioid receptor; DAMGO: Tyr-Ala-Gly-N-
Me-Phe-Gly-ol, DPDPE-OH: Tyr-Pen-Gly-Phe-Pen-OH [disulfide bridge: 2-5]; U-69,593: (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-
oxaspiro[4.5]dec-8-yl]-benzeneacetamide; 
 
U-50,488H: trans-(±)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide 
methanesulfonate salt; Nor-BNI: norbinaltorphimine; U-69,593: (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-
benzeneacetamide. SEM: standard error of the mean.  
Numbers represent the means ± SEM from at least three independent experiments, each conducted with duplicate determinations. 
Standard compounds were the agonists DPDPE (delta), U50,488H (kappa) and DAMGO (mu) and the antagonists naltrexone (delta and 
mu) and nor-BNI (kappa). 
c
 Maximal stimulation by test compound is normalized to the maximal stimulation by DPDPE (delta), U50,488H (kappa) or DAMGO (mu) 
above basal. Negative values indicate inhibition of basal [
35
S]GTPγS binding. 
b
 pFBF:  p-Fluoro-butyrylfentanyl. 
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p-Fluoro-butyrylfentanyl showed a higher potency in eliciting antinociception 
compared to locomotor stimulation. Straub tail was observed after administering all 
three drugs during tail-withdrawal tests and it was stated that other obvious and 
unusual signs were not observed.40  
 
Table 2. Antinociceptive effects using the warm-water tail-withdrawal procedure.
40
  
Test drug ED50 (mg/kg) 
p-Fluoro-butyrylfentanyl 0.9081 
p-Fluoro-butyrylfentanyl + naltrexone (1 mg/kg) 9.8740 
Fentanyl  0.0801 
Fentanyl + naltrexone (1 mg/kg) 0.3162 
Morphine 7.8210 
Morphine + naltrexone (1 mg/kg) 11.5900 
 
5. Toxicology 
No information could be identified.  
6. Adverse Reactions in Humans 
The US Centers for Disease Control and Prevention estimated that drug overdose 
deaths involving synthetic opioids (excluding methadone) for the 12-month period 
ending in January of 2017 (20,145 deaths) increased significantly compared to the 
cases counted for the period ending in January of 2016 (9,945 deaths).41 However, 
specific information related to a causal relationship of p-fluoro-butyrylfentanyl with 
adverse reactions is limited. One potential reason includes the challenges that 
might arise from the analytical differentiation from the p-fluoro-isobutyrylfentanyl 
isomer. For example, in 17 death cases reported to the US Drug Enforcement 
Administration, the analyses of postmortem blood samples included the 
identification of “p-fluoro-butyrylfentanyl/p-fluoro-isobutyrylfentanyl” presumably 
as a reflection of this challenge. p-Fluoro-butyrylfentanyl/p-fluoro-
isobutyrylfentanyl was the constituent detected at the highest concentrations and 
thus might have been the main contributor to these deaths. Other drugs of abuse 
(including fentanyl analogs) have also been detected.  
 
A case of acute intoxication occurring in January 2015 in Sweden and associated 
with the detection of p-fluoro-butyrylfentanyl involved a 25-year old male who 
presented with disorientation, unsteady, slurred speech and hypotension (90/60 
mmHg) (poisoning severity score = 1). The patient was awake and displayed miotic 
pupils. He also reported the intake of “one pill” ∼9 h prior to blood and urine 
sampling in the emergency department.  The analysis of biofluids taken ~ 1h after 
admission revealed estimated p-fluoro-butyrylfentanyl concentrations of 15.0 
ng/mL (serum), 9.5 μg/mL (urine), and 1.4 μg/mmol creatinine (urine). Pregabalin, 
tramadol, O-desmethyltramadol, 4-hydroxyalprazolam, and oxazepam were also 
detected.16 p-Fluoro-butyrylfentanyl (not quantified), together other fentanyl 
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analogs and prescription medicines were detected in two cases associated with an 
acute intoxication involving p-methoxy-butyrylfentanyl.30 
 
Two death cases associated with p-fluoro-butyrylfentanyl were reported from 
Poland (Table 3).12  
 
Table 3. Death cases involving the detection of p-fluoro-butyrylfentanyl in Poland 
Year a Patent, 
age 
Comments Ref 
2017 M, 26 Found dead at home. An electronic cigarette and e-liquid 
were found near the deceased. p-Fluoro-butyrylfentanyl 
was identified in e-liquid (35 mg/mL); glycerol was the 
main matrix and nicotine was also detected.  
 
p-Fluoro-butyrylfentanyl detections in biological samples: 
91 ng/mL (blood); 200 ng/mL (urine); 902 ng/g (liver); 411 
ng/g (kidney); 248 ng/g (brain), 8450 ng/g (stomach).  
12 
2017 F, 26 Found dead at home; known as occasional user of new 
psychoactive substances and “drugs”. A plastic bag with a 
light-yellow powder was found near the deceased.  
Powder was identified as p-fluoro-butyrylfentanyl.  
 
p-Fluoro-butyrylfentanyl detections in biological samples: 
112 ng/mL (blood); 414 ng/mL (urine); 136 ng/g (liver); 
197 ng/g (kidney).  
12 
a
 Year of publication. Cases occurred in 2015. 
 
The detection of other substances has not been reported. A 2017 case series (22 
male, 3 female, January to May) from the United Kingdom revealed the detection of 
p-fluoro-butyrylfentanyl in biological samples obtained from acute intoxication and 
death cases (12/22 cases). Carfentanil concentrations were predominant but a 
range of other fentanyl analogs (including p-fluoro-butyrylfentanyl but not 
quantified), benzodiazepines, markers for street heroin use, and other substances 
were also detected.20 
7. Dependence Potential 
A. Animal Studies 
Studies that have investigated the dependence potential of p-fluoro-butyrylfentanyl 
in animals could not be identified. 
B. Human Studies 
Studies that have investigated the dependence potential of p-fluoro-butyrylfentanyl 
in humans could not be identified. However, it is well established that opioid 
analgesics such as fentanyl can induce tolerance and dependence. Further research 
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might be required in order to investigate these effects with p-fluoro-
butyrylfentanyl. 
8. Abuse Potential 
A. Animal Studies 
Studies that have investigated the abuse potential of p-fluoro-butyrylfentanyl in 
animals could not be identified.  
B. Human Studies 
Studies that have investigated the abuse potential of p-fluoro-butyrylfentanyl in 
humans could not be identified although cases of analytically confirmed ingestions 
have been reported (Section 6). 
9. Therapeutic Applications and Extent of Therapeutic Use and Epidemiology of 
Medical Use 
Information about therapeutic use could not be identified. 
10. Listing on the WHO Model List of Essential Medicines 
p-Fluoro-butyrylfentanyl is not listed. 
11. Marketing Authorizations (as a Medicinal Product) 
p-Fluoro-butyrylfentanyl was never marketed as a medicinal product.   
12. Industrial Use 
Information about recorded industrial use could not be identified. 
 
13. Non-Medical Use, Abuse and Dependence 
Surveys that systematically assess the prevalence of p-fluoro-butyrylfentanyl use within the 
general population are not available. The detection of p-fluoro-butyrylfentanyl in biological 
fluids confirms that this substance is used recreationally (Sections 4 and 6). The available 
information suggests that the use of this substance is associated with individuals who 
might be abusing/misusing heroin and prescription opioid analgesics and heroin. p-Fluoro-
butyrylfentanyl might also have attracted the attention of experimental substance users 
(psychonauts) (Section 4).  
14. Nature and Magnitude of Public Health Problems Related to Misuse, Abuse and 
Dependence 
Data on the effects of p-fluoro-butyrylfentanyl on the ability to drive and operate machines 
could not be identified. Since it is well established that opioid analgesics, such as fentanyl, 
impact on the mental and physical ability required for driving and operating machinery, it is 
likely that this might also extend to p-fluoro-butyrylfentanyl. Some of these substances 
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may be sold as another substance and/or are not always labeled, a phenomenon that has 
been observed with the use of other fentanyl analogs. Examples exist where p-fluoro-
butyrylfentanyl was detected as an adulterant in samples of heroin obtained from the 
cryptomarket.42 The US Drug Enforcement Administration reported the detection of 
cocaine samples adulterated with fentanyl and fentanyl analogs. The detections occurred 
in seized samples obtained in the period from 2016–2017 in Florida (USA).43 Marginalized 
and vulnerable opioid users including those who inject such substances also use fentanyl 
analogs. However, users may not be aware of using them and the high potency associated 
with fentanyl analogs might result in increased risks of life-threatening overdoses. 
 
The observation that p-fluoro-butyrylfentanyl and other analogs are also available in the 
form of nasal sprays (a case of a p-fluoro-butyrylfentanyl containing e-liquid has also been 
reported) raises questions as to whether these dosage forms might render the use of 
fentanils more attractive and/or socially acceptable.28 Further studies are warranted to 
assess whether this might be associated with the attraction of new user groups.  
 
The high potency of fentanyl and its analogs pose a serious risk of accidental exposure to 
products with the potential for subsequent poisoning of the public, law enforcement and 
emergency personnel, as well as medical/laboratory personnel.27, 28 
 
15. Licit Production, Consumption and International Trade 
It is used as a reference material for scientific research. It is not known to have any 
agricultural, industrial or cosmetic uses even though it is available for purchase as a 
‘research chemical’. Please refer to Annex 1: Report on WHO questionnaire for review of 
psychoactive substances. 
16. Illicit Manufacture and Traffic and Related Information 
Reports have been received from the European Early-Warning System on new 
psychoactive substances that p-fluoro-butyrylfentanyl (first notified to EMCDDA in March 
201444) was encountered in seizures and collected specimen (powder and tablets) in 
Latvia, Slovenia, Sweden and Poland.29  
 
The background information and evaluation of ‘Three Factor Analysis’ (Factors 4, 5 and 6) 
for temporary scheduling document45 states that the identification of p-fluoro-
butyrylfentanyl was featured in five reports since September 2014 (STRIDE and STARLiMS 
queries). The National Forensic Laboratory Information System (NFLIS), which is dedicated 
to the collection of drug cases submitted by State and local laboratories in the USA, has 
recorded 220 reports when queried on November 3, 2017.46 According to the Drug 
Enforcement Administration's (DEA) Special Testing and Research Laboratory’s Emerging 
Trends Program, p-fluoro-butyrylfentanyl was identified in 3 out of 1299 identifications of 
fentanyl and fentanyl related substances (and other new opioids).47 
 
Detections of p-fluoro-butyrylfentanyl have also been reported to the United Nations 
Office on Drugs and Crime’s (UNODC) Early Warning Advisory on New Psychoactive 
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Substances. Detections of p-fluoro-butyrylfentanyl were reported by three countries in 
2015, five countries in 2016, and one country in 2017 (as of 25 August 2018).48 
 
Please also refer to Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
17. Current International Controls and Their Impact 
p-Fluoro-butyrylfentanyl is not controlled under the 1961, 1971 or 1988 United Nations 
Conventions. 
18. Current and Past National Controls 
Refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
 
19. Other Medical and Scientific Matters Relevant for a Recommendation on the 
Scheduling of the Substance 
Detections of p-fluoro-butyrylfentanyl may be under-reported given that the substance 
might not be routinely screened for in all laboratories receiving samples for analysis.  
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